See more : Anjani Synthetics Limited (ANJANI.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Siemens Healthineers AG (SHL.DE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Siemens Healthineers AG, a leading company in the Medical – Devices industry within the Healthcare sector.
- The Phoenix Holdings Ltd. (PHOE.TA) Income Statement Analysis – Financial Results
- Porton Pharma Solutions Ltd. (300363.SZ) Income Statement Analysis – Financial Results
- Miahona Co. (2084.SR) Income Statement Analysis – Financial Results
- Playground Ventures Inc. (SMPBF) Income Statement Analysis – Financial Results
- MAHLE Metal Leve S.A. (LEVE3.SA) Income Statement Analysis – Financial Results
Siemens Healthineers AG (SHL.DE)
About Siemens Healthineers AG
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. The company operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. The Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory, molecular and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, and solutions and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services and consulting capabilities, and digital solutions and applications for managing treatment and therapy. The Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms, including a robotic-assisted platform for endovascular coronary and peripheral vascular interventions. It also provides equipment performance management, clinical education and e-learning, asset management, and managed departmental services for laboratories and healthcare facilities, as well as consulting and digital health services. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.36B | 21.68B | 21.71B | 18.00B | 14.46B | 14.52B | 13.43B | 13.80B | 13.55B | 12.94B |
| Cost of Revenue | 13.90B | 13.97B | 13.58B | 11.05B | 8.88B | 8.72B | 7.96B | 8.03B | 8.08B | 7.87B |
| Gross Profit | 8.47B | 7.71B | 8.14B | 6.95B | 5.58B | 5.80B | 5.47B | 5.76B | 5.47B | 5.07B |
| Gross Profit Ratio | 37.87% | 35.56% | 37.47% | 38.63% | 38.59% | 39.92% | 40.72% | 41.77% | 40.36% | 39.19% |
| Research & Development | 1.92B | 1.87B | 1.79B | 1.55B | 1.34B | 1.33B | 1.28B | 1.25B | 1.15B | 1.06B |
| General & Administrative | 3.68B | 3.61B | 3.41B | 2.82B | 2.28B | 2.21B | 2.15B | 2.22B | 2.21B | 2.11B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.68B | 3.61B | 3.41B | 2.82B | 2.28B | 2.21B | 2.15B | 2.22B | 2.21B | 2.11B |
| Other Expenses | 0.00 | 103.00M | 20.00M | 32.00M | 15.00M | -42.00M | 73.00M | -3.00M | -1.00M | -58.00M |
| Operating Expenses | 5.60B | 5.58B | 5.21B | 4.40B | 3.64B | 3.50B | 3.51B | 3.47B | 3.35B | 3.11B |
| Cost & Expenses | 19.49B | 19.55B | 18.79B | 15.44B | 12.52B | 12.22B | 11.47B | 11.51B | 11.43B | 10.97B |
| Interest Income | 119.00M | 85.00M | 48.00M | 33.00M | 53.00M | 38.00M | 41.00M | 12.00M | 14.00M | 19.00M |
| Interest Expense | 476.00M | 296.00M | 118.00M | 83.00M | 76.00M | 123.00M | 205.00M | 267.00M | 216.00M | 117.00M |
| Depreciation & Amortization | 1.22B | 1.56B | 1.34B | 1.04B | 815.00M | 620.00M | 530.00M | 572.00M | 591.00M | 563.00M |
| EBITDA | 4.22B | 3.78B | 4.26B | 3.52B | 2.84B | 2.93B | 2.53B | 2.81B | 2.72B | 2.55B |
| EBITDA Ratio | 18.88% | 17.44% | 19.62% | 19.53% | 19.44% | 20.22% | 18.87% | 20.90% | 20.12% | 19.76% |
| Operating Income | 2.87B | 2.22B | 2.92B | 2.48B | 2.00B | 2.32B | 1.96B | 2.29B | 2.12B | 1.96B |
| Operating Income Ratio | 12.83% | 10.26% | 13.44% | 13.76% | 13.80% | 15.95% | 14.60% | 16.60% | 15.63% | 15.17% |
| Total Other Income/Expenses | -344.00M | -205.00M | -124.00M | -59.00M | -41.00M | -103.00M | -162.00M | -246.00M | -199.00M | -87.00M |
| Income Before Tax | 2.53B | 1.93B | 2.80B | 2.40B | 1.95B | 2.19B | 1.80B | 2.04B | 1.92B | 1.88B |
| Income Before Tax Ratio | 11.29% | 8.89% | 12.89% | 13.36% | 13.51% | 15.11% | 13.40% | 14.82% | 14.16% | 14.50% |
| Income Tax Expense | 564.00M | 403.00M | 746.00M | 658.00M | 532.00M | 607.00M | 515.00M | 600.00M | 590.00M | 584.00M |
| Net Income | 1.94B | 1.51B | 2.04B | 1.73B | 1.41B | 1.57B | 1.27B | 1.43B | 1.31B | 1.28B |
| Net Income Ratio | 8.68% | 6.96% | 9.39% | 9.60% | 9.76% | 10.79% | 9.42% | 10.34% | 9.68% | 9.87% |
| EPS | 1.74 | 1.35 | 1.82 | 1.57 | 1.41 | 1.57 | 1.27 | 1.38 | 1.31 | 1.28 |
| EPS Diluted | 1.74 | 1.34 | 1.81 | 1.56 | 1.41 | 1.57 | 1.26 | 1.38 | 1.31 | 1.28 |
| Weighted Avg Shares Out | 1.12B | 1.12B | 1.12B | 1.10B | 1.00B | 999.25M | 999.90M | 1.00B | 1.00B | 1.00B |
| Weighted Avg Shares Out (Dil) | 1.12B | 1.12B | 1.13B | 1.10B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B |
Source: https://incomestatements.info
Category: Stock Reports